Pasar al contenido principal


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Conexión rápida

Nota informativa

Substantially Pure Carfilzomib Amorphous for Generic Launch

Substantially Pure Carfilzomib Amorphous for Generic Launch

Kyprolis (carfilzomib) is a proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic tumour cells. In animals, carfilzomib inhibited proteasome activity in blood and tissue and delayed tumour growth.

Dr. Reddy's API Offering

Dr. Reddy’s Carfilzomib API is a notable example of the technical capabilities of product development. It offers our customers access to a generic API that shows distinct features of having optimal consumption co-efficient in line with the green chemistry concept and superlative quality resulting from a robust process at scale.

  • We manufacture Carfilzomib amorphous API at our cGMP API manufacturing facility, successfully inspected by international regulatory authorities - USFDA, KFDA, WHO- GMP, Russian Federation, and ANVISA (document-based inspection completed and certificate is available).
  • To achieve high supply assurance, our key starting materials (KSM) are sourced domestically, and one is from China.
  • Continuous improvement is in place to achieve quality and supply excellence.
  • The current batch size is about 1.5 kg (Per customer requirement, discrete lots can be supplied).

To learn more about our API offerings, please read the product alert Carfilzomib API by filling out the contact form below.

Explore other Whitepapers:

Know More

Download Now

Complete el formulario de contacto a continuación para ver el documento técnico

Nuestra lienea de contacto email: api@drreddys.com | +91 40 49002222

Renuncia

Ninguna información en este catálogo, incluida cualquier referencia a cualquier producto o servicio, constituye una oferta de venta, ni debe interpretarse como representación de una oferta de venta. Los productos protegidos por patentes válidas no se ofrecen ni se suministran para uso comercial. Sin embargo, las cantidades de investigación de dichos productos pueden ofrecerse con el fin de presentaciones reglamentarias, siempre que existan dichas exenciones reglamentarias. Los compradores deben realizar una evaluación independiente del escenario de la patente para sus respectivos mercados y serán responsables de todas las responsabilidades relacionadas con la patente. Los productos protegidos por patentes válidas en la India no están disponibles para uso comercial, pero estarían disponibles para los fines de la Sección 107A.

X
Checked out our

API Linkedin
page yet?

Follow this page to explore how our offerings can accelerate your formulation success

Click here to visit